{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:15:36Z","timestamp":1788992136900,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jgar.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:12:24Z","timestamp":1778080344000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of antibiotics in the treatment of multidrug-resistant Acinetobacter baumannii infections: A systematic review and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8878-958X","authenticated-orcid":false,"given":"Binh Van","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phi Yen","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-814X","authenticated-orcid":false,"given":"Tu Tuan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao Bui","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Wai","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.jgar.2026.04.016_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0002","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis","volume":"79","author":"Mohd Sazlly Lim","year":"2019","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.jgar.2026.04.016_bib0003","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.jgar.2026.04.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00213-21","article-title":"Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition","volume":"59","author":"Humphries","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.jgar.2026.04.016_bib0005","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jgar.2026.04.016_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial antibiotic resistance: the most critical pathogens","volume":"10","author":"Mancuso","year":"2021","journal-title":"Pathogens"},{"issue":"12","key":"10.1016\/j.jgar.2026.04.016_bib0007","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-014-0267-8","article-title":"Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections","volume":"74","author":"Viehman","year":"2014","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2026.04.016_bib0008","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","article-title":"Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997-2016)","volume":"6","author":"Gales","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.jgar.2026.04.016_bib0011","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jgar.2026.04.016_bib0012","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.04.016_bib0013","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.04.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jgar.2026.04.016_bib0015","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkad284","article-title":"Neurological burden and outcomes of excessive \u03b2-lactam serum concentrations of critically ill septic patients: a prospective cohort study","volume":"78","author":"Zerbib","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0016","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper(","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.jgar.2026.04.016_bib0017","article-title":"Mechanisms of antibiotic resistance in important gram-positive and gram-negative pathogens and novel antibiotic solutions","volume":"10","author":"Kakoullis","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.jgar.2026.04.016_bib0018","doi-asserted-by":"crossref","first-page":"180","DOI":"10.37349\/eds.2023.00013","article-title":"Approved antibacterial drugs in the last 10 years: from the bench to the clinic","volume":"1","author":"Garc\u00eda-Castro","year":"2023","journal-title":"Explor Drug Sci"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0019","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jgar.2026.04.016_bib0020","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2026.04.016_bib0021","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2026.04.016_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000858","article-title":"Synthesising quantitative evidence in systematic reviews of complex health interventions","volume":"4","author":"Higgins","year":"2019","journal-title":"BMJ Glob Health"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0023","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"key":"10.1016\/j.jgar.2026.04.016_bib0024","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"key":"10.1016\/j.jgar.2026.04.016_bib0026","series-title":"the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care","first-page":"R204","article-title":"Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs","volume":"8","author":"Bellomo","year":"2004"},{"issue":"4","key":"10.1016\/j.jgar.2026.04.016_bib0027","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"10","key":"10.1016\/j.jgar.2026.04.016_bib0028","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0029","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias visualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jgar.2026.04.016_bib0030","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"205","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jgar.2026.04.016_bib0031","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jgar.2026.04.016_bib0032","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J Royal Statistical Soc: Series B (Statistic Methodol)"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0033","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"Van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jgar.2026.04.016_bib0034","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"issue":"8","key":"10.1016\/j.jgar.2026.04.016_bib0036","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/sim.7223","article-title":"Combining randomized and non-randomized evidence in network meta-analysis","volume":"36","author":"Efthimiou","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2026.04.016_bib0037","series-title":"gemtc: network meta-analysis using Bayesian methods (version 1.1-0)","author":"Van Valkenhoef","year":"2025"},{"issue":"7454","key":"10.1016\/j.jgar.2026.04.016_bib0038","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2026.04.016_bib0039","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"Higgins","year":"2024"},{"key":"10.1016\/j.jgar.2026.04.016_bib0040","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jgar.2026.04.016_bib0041","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0042","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0043","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.jgar.2026.04.016_bib0044","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jiac.2017.01.005","article-title":"Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2017","journal-title":"J Infect Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jgar.2026.04.016_bib0046","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2026.04.016_bib0047","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107190","article-title":"Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multi-centre clinical experience","volume":"64","author":"Russo","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0049","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10096-024-04833-8","article-title":"Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study","volume":"43","author":"Oliva","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0050","article-title":"Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study","volume":"12","author":"Dalfino","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"9","key":"10.1016\/j.jgar.2026.04.016_bib0051","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.jgar.2026.04.016_bib0052","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad329","article-title":"Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic","volume":"10","author":"Giannella","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jgar.2026.04.016_bib0053","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol versus colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"5","key":"10.1016\/j.jgar.2026.04.016_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2026.04.016_bib0055","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jgar.2026.04.016_bib0056","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1186\/s12879-024-09899-5","article-title":"Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis","volume":"24","author":"Zhan","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.jgar.2026.04.016_bib0057","article-title":"Cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii","volume":"12","author":"Karruli","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"9","key":"10.1016\/j.jgar.2026.04.016_bib0058","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jgar.2026.04.016_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106271","article-title":"Enhanced bacterial killing with colistin\/sulbactam combination against carbapenem-resistant Acinetobacter baumannii","volume":"57","author":"Bian","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.04.016_bib0060","article-title":"Synergistic antibacterial activity of combined antimicrobials and the clinical outcome of patients with carbapenemase-producing Acinetobacter baumannii infection","volume":"11-2020","author":"Qu","year":"2020","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.jgar.2026.04.016_bib0061","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.04.016_bib0062","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"7","key":"10.1016\/j.jgar.2026.04.016_bib0063","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/AAC.00070-14","article-title":"Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways","volume":"58","author":"Dai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jgar.2026.04.016_bib0064","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/CCM.0000000000000931","article-title":"Association between colistin dose and development of nephrotoxicity","volume":"43","author":"Lee","year":"2015","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.jgar.2026.04.016_bib0065","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jgar.2026.04.016_bib0066","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.04.016_bib0067","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619885529","article-title":"Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria","volume":"13","author":"Choe","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"10.1016\/j.jgar.2026.04.016_bib0068","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3947\/ic.2024.0055","article-title":"Optimizing treatment for carbapenem-resistant Acinetobacter baumannii complex infections: a review of current evidence","volume":"56","author":"Choi","year":"2024","journal-title":"Infect Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:28:36Z","timestamp":1781767716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":68,"alternative-id":["S2213716526000664"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.04.016","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of antibiotics in the treatment of multidrug-resistant Acinetobacter baumannii infections: A systematic review and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}